The effect of chemotherapy on health-related quality of life in mesothelioma: Results from the SWAMP trial

British Journal of Cancer

Volumn 112, Issue 7, 2015, Pages 1183-1189

  Arnold, D T ^a   Hooper, C E ^a,b   Morley, A ^b   White, P ^c   Lyburn, I D ^d   Searle, J ^d   Darby, M ^e   Hall, T ^f   Hall, D ^d   Rahman, N M ^g   De Winton, E ^f   Clive, A ^a   Masani, V ^f   Dangoor, A ^h   Guglani, S ⁱ   Jankowska, P ^j   Lowndes, S A ^k   Harvey, J E ^b   Braybrooke, J P ^h   Maskell, N A ^a,b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

^c UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

^d Cobalt Health   (United Kingdom)

^e NORTH BRISTOL NHS TRUST   (United Kingdom)

^f ROYAL UNITED HOSPITAL   (United Kingdom)

^g CHURCHILL HOSPITAL   (United Kingdom)

^h BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

ⁱ CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

^j MUSGROVE PARK HOSPITAL   (United Kingdom)

^k GREAT WESTERN HOSPITAL   (United Kingdom)

more..

Author keywords

Chemotherapy; Mesothelioma; Quality of life

Indexed keywords

CARBOPLATIN; CISPLATIN; MESOTHELIN; PEMETREXED; ANTINEOPLASTIC AGENT; GLUTAMIC ACID DERIVATIVE; GUANINE; TUMOR MARKER;

ADULT; AGED; ALOPECIA; ARM PAIN; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER PAIN; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DYSPNEA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MOUTH PAIN; MULTICENTER STUDY; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; QUESTIONNAIRE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; LUNG NEOPLASMS; MESOTHELIOMA; MIDDLE AGED; PALLIATIVE THERAPY; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CARBOPLATIN; CISPLATIN; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PALLIATIVE CARE; PEMETREXED; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 84938551132     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.77     Document Type: Article

References (25)

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5): 365-376.
2. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M (1994) The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 30A(5): 635-642.
3. Boons CC, VANT MW, Burgers JA, Beckeringh JJ, Wagner C, Hugtenburg JG (2013) The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review. Anticancer Res 33(9): 3553-3561.
4. Bottomley A, Gaafar R, Manegold C, Burgers S, Coens C, Legrand C, Vincent M, Giaccone G, Van Meerbeeck J. Group EL-C, National Cancer Institute C (2006) Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. J Clin Oncol 24(9): 1435-1442.
5. Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15(2): 257-260.
6. Chapman A, Mulrennan S, Ladd B, Muers MF (2008) Population based epidemiology and prognosis of mesothelioma in Leeds, UK. Thorax 63(5): 435-439.
7. Creaney J, Francis RJ, Dick IM, Musk AW, Robinson BW, Byrne MJ, Nowak AK (2011) Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res 17(5): 1181-1189.
8. Creaney J, Robinson BW (2005) Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein. Hematol Oncol Clin North Am 19(6): 1025-1040v.
9. Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35(11): 1095-1108.
10. Flechtner H, Bottomley A (2003) Fatigue and quality of life: lessons from the real world. Oncologist 8(Suppl 1): 5-9.
11. Grigoriu BD, Scherpereel A (2008) Diagnostic value of soluble mesothelin in malignant mesothelioma. Thorax 63(1): 87-88author reply 87.
12. Hooper CE, Lyburn I, Searle J, Darby M, Hall T, Hall D, Morley A, White P, Rahman N, De Winton E, Clive A, Masani V, Arnold D, Dangoor A, Guglani S, Jankowska P, Lowndes S, Harvey JE, Braybrooke J, Maskell NA (2015) The South West Area Mesothelioma and Pemetrexed (SWAMP) trial - A multi-centre prospective observational study evaluating novel markers of chemotherapy response and prognostication. Br J Cancer.
13. HSCIC HaSCIC (2014) National Lung Cancer Audit Report 2014 (Mesothelioma).
14. Kao SC, Vardy J, Harvie R, Chatfield M, van Zandwijk N, Clarke S, Pavlakis N (2013) Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. Support Care Cancer 21(3): 697-705.
15. Kwek BH, Aquino SL, Fischman AJ (2004) Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis. Chest 125(6): 2356-2360.
16. Longworth L, Rowen D (2013) Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health 16(1): 202-210.
17. Muers MF, Rudd RM, O'Brien ME, Qian W, Hodson A, Parmar MK, Girling DJ. British Thoracic Society Mesothelioma G (2004) BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112. Thorax 59(2): 144-148.
18. Musk AW, Olsen N, Alfonso H, Reid A, Mina R, Franklin P, Sleith J, Hammond N, Threlfall T, Shilkin KB, de Klerk NH (2011) Predicting survival in malignant mesothelioma. Eur Respir J 38(6): 1420-1424.
19. Neumann V, Rutten A, Scharmach M, Muller KM, Fischer M (2004) Factors influencing long-term survival in mesothelioma patients-results of the German mesothelioma register. Int Arch Occup Environ Health 77(3): 191-199.
20. NICE (2008) Pemetrexed for the treatment of malignant pleural mesothelioma. NICE Technology Appraisal Guidance 135.
21. Nowak AK, Stockler MR, Byrne MJ (2004) Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module. J Clin Oncol 22(15): 3172-3180.
22. Pickard AS, Neary MP, Cella D (2007) Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 5: 70.
23. Rintoul RC, Ritchie AJ, Edwards JG, Waller DA, Coonar AS, Bennett M, Lovato E, Hughes V, Fox-Rushby JA, Sharples LD. MesoVatsCollaborators (2014) Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet 384(9948): 1118-1127.
24. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14): 2636-2644.
25. Yates DH, Corrin B, Stidolph PN, Browne K (1997) Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. Thorax 52(6): 507-512.